Skip to main content
. 2017 Apr 18;3(2):124–136. doi: 10.1007/s40778-017-0077-5

Table 1.

Published clinical trials using CD19/20 CAR T cells

Target antigen Target disease n CAR structure Delivery method Origin of T cell Cell dose Trial number Center Reference
CD19 FL 2 CD3ζ EP Autologous 100–2000 × 106/m2 NCT00182650 NCI Jensen (2010) [75]
CD19 FL 1 CD28 + CD3ζ RV Autologous 5 × 106/kg NCT00924326 NCI Kochenderfer (2010) [69]
CD19 FL; DLBCL 6 CD28 + CD3ζ RV Autologous 2–20 × 107/m2 BCM Savoldo (2011) [76]
CD19 CLL; ALL 10 CD28-CD3ζ RV Autologous 0.4, 1, 3 × 107/kg over 2 days NCT01044069 MSKCC Brentjens (2011) [77]
CD19 CLL 3 4-1BB + CD3ζ LV Autologous 0.15–16 × 106/kg NCT01029366 Upenn Porter (2011) [78]; Kalos (2011) [70]
CD19 CLL; ALL 9 CD28 + CD3ζ RV Autologous 2–30 × 106/kg NCT00466531 MSKCC Brentjens (2011) [77]
CD19 FL; CLL; SMZL 8 CD28 + CD3ζ RV Autologous 5–55 × 106/kg NCT00924326 NCI Kochenderfer (2012) [79]
CD19 ALL 5 CD28 + CD3ζ RV Autologous 1.5–3 × 106/kg NCT01044069 MSKCC Brentjens (2013) [71]
CD19 CLL; MCL; DLBCL 10 CD28 + CD3ζ RV Allogeneic 1–100 × 106/kg NCT01087294 NCI Kochenderfer (2013) [80]
CD19 ALL; CLL 8 CD28-CD3ζ RV Allogeneic 1.5, 4.5, 12 × 107/m2 NCT00840853 BCM Cruz (2013) [81]
CD19 CLL; ALL; DLBCL; FL; MCL 110 4-1BB-CD3ζ RV Autologous 1.5–500 × 107 total cells NCT01029366 Upenn Maude (2014) [82•]
CD19 ALL 2 4-1BB-CD3ζ LV Autologous 10–100 × 106/kg NCT01626495 Upenn Maude (2014) [82•]
CD19 ALL 30 4-1BB-CD3ζ LV Autologous 0.76–20.6 × 106/kg NCT01626495 Upenn Maude (2014) [82•]
CD19 ALL; CLL 14 CD28-CD3ζ RV Autologous 0.2, 1, 2 × 108/m2 NCT00586391 BCM Xu (2014) [83]
CD19 CLL 4 CD28-CD3ζ RV Autologous 1–4 × 106/kg NCT00924326 NCI Kochenderfer (2015) [84]
CD19 ALL 21 CD28-CD3ζ RV Autologous 1, 3 × 106/kg NCT01593696 NCI Lee (2015) [85]
CD19 MM 10 4-1BB-CD3ζ LV Autologous 1–5 × 107 NCT02135406 Upenn Garfall (2015) [86]
CD19 NHL 7 CD28-CD3ζ SBT Autologous/allogeneic 1 × 106/m2 NCT00968760 MDACC Kebriaei (2016) [87]
19 1 × 106/m2 NCT01497184
CD19 CLL, SLL, MM 42 4-1BB-CD3ζ LV Autologous 1–5 × 107/8 NCT01747486 Upenn Fraietta (2016) [88]
CD20 MCL; B-NHL 3 CD28–4-1BB-CD3ζ EP Autologous 108, 109, 3.3 × 109/m2 NCT00621452 FHCRC Till (2012) [89]
CD20 DLBCL 7 4-1BB-CD3ζ LV Autologous ∼0.3–2.2 × 107/kg NCT01735604 CPLAGH Wang (2014) [90]

FL follicular lymphoma, MCL mantle cell lymphoma, CLL chronic lymphocytic leukemia, ALL acute lymphoblastic leukemia, BL Burkitt lymphoma, DLBCL diffuse large B cell lymphoma, HL Hodgkin’s lymphoma, NHL non-Hodgkins lymphoma, MM multiple myeloma, EP electroporation, RV retrovirus, LV lentivirus, SBT Sleeping Beauty transposition, BCM Baylor College of Medicine, NCI National Cancer Institute, FHCRC Fred Hutchinson Cancer Research Center, UPenn University of Pennsylvania, MSKCC Memorial Sloan Kettering Cancer Center, MDACC MD Anderson Cancer Center, CPLAGH Chinese PLA General Hospital